Clinical TrialJul 15, 2026, 07:51 AM
Ernexa ERNA-101 Preclinical Data Validated; IND Q3 2026
AI Summary
Ernexa Therapeutics announced compelling new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition. The study successfully reproduced earlier findings, demonstrating complete tumor clearance and durable long-term survival in 67% of treated animals, with no complete responses in monotherapy or control groups. This validation strengthens confidence as the company plans its IND submission in Q3 2026 and anticipates a first-in-human Phase 1 clinical trial in Q4 2026.
Key Highlights
- Independent CRO successfully reproduced ERNA-101 combination data in a larger preclinical study.
- ERNA-101 plus anti-PD-1 achieved complete tumor clearance and long-term survival in 67% of treated animals.
- No complete responses were observed in any monotherapy or control groups.
- Investigational New Drug (IND) submission planned for Q3 2026.
- First-in-human Phase 1 trial expected to begin in Q4 2026.
Price Impact
More from ERNA